Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab in Advanced Solid Tumors
NCT02281409Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2014
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mogamulizumab in solid tumor, triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 1 more (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 1 year. Started Oct 2014; status: completed.
02
Drugs
mogamulizumab
03
Conditions
solid tumortriple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT02281409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281409.